New research project on BPAN in Tübingen

New research project on BPAN in Tübingen

Tübingen research group led by Professor Tassula Proikas-Cezanne and Hoffnungsbaum e.V. are joining forces in the research of BPAN

Deciphering the causes of rare, neurodegenerative diseases is a lengthy process that is associated with much hope and great suffering for those affected. In a new research project, Professor Tassula Proikas-Cezanne from the University of Tübingen is investigating the molecular causes of the rare disease "BPAN (beta propeller-associated neurodegeneration)". She is working with doctors in Tübingen, London and Copenhagen as well as the patient organizations "Hoffnungsbaum e.V." in Germany and "BPAN Warriors" in the USA to investigate the cellular causes and potential treatment options. The project is funded by the German Research Foundation (DFG) as part of the Frankfurt Collaborative Research Center SFB 1177.
BPAN (beta propeller-associated neurodegeneration) is a very rare, congenital neurodegenerative disease caused by a mutation of the WDR45/WIPI4 gene on the X chromosome. Patients are characterized from birth by a severe developmental disorder that is associated with epilepsy, mental and physical disabilities and pronounced impairments in language acquisition. Painful muscle spasms and symptoms of Parkinson's disease set in later. The life expectancy of patients is significantly shortened and there is currently no treatment. BPAN belongs to a group of more than ten diseases called NBIA (neurodegeneration with iron deposition in the brain). Around 20 patients with BPAN are known in Germany.

The autophagy researcher Professor Tassula Proikas-Cezanne, molecular biologist at the University of Tübingen and discoverer of the WDR45/WIPI4 gene, will be working in the next four years as part of the Collaborative Research Center SFB 1177 ("Molecular and Functional Characterization of Selective Autophagy", Speaker: Prof. Dr. Ivan Dikic, Goethe University, Frankfurt a.M.) are investigating the process of autophagy in brain cells of BPAN patients. A few years ago, Proikas-Cezanne recognized that the WDR45/WIPI4 gene plays an important functional role in the process of autophagy. Autophagy is a cellular degradation and renewal system that is disrupted in the nerve cells of patients with many neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Due to the mutation in the WDR45/WIPI4 gene, autophagy in BPAN is severely impaired, but the causative molecular mechanisms are unknown. The scientist would like to elucidate these mechanisms and will be working closely with neurologist Professor Matthis Synofzik from the University Hospital in Tübingen and other colleagues in London and Copenhagen.

The researchers are supported by "Hoffnungsbaum e.V.", the German patient organization for the promotion of research and treatment of NBIA. The association has already initiated, co-financed or accompanied several research projects over the past 15 years and is also very well networked internationally. "In this strategic partnership, we can act in particular as a contact and information interface between the researchers and our patient network. Added to this is, of course, the knowledge of the affected families about their children's BPAN disease," explains Angelika Klucken, Chairwoman and co-founder of "Hoffnungsbaum e.V.".

"I am delighted and thrilled that we have found such a renowned and committed comrade-in-arms in the fight against BPAN in Professor Proikas-Cezanne," says Markus Nielbock, father of seven-year-old Emilia, who suffers from BPAN, and second chairman of "Hoffnungsbaum e.V.". "We will do everything we can to support her and Professor Synofzik."

For Tassula Proikas-Cezanne, this research project also stands out from other projects in her research group. "The fact that a spontaneous mutation of a gene that I discovered years ago can trigger such a serious disease obliges me to focus our research interests here," she explains. "The personal contact with children suffering from BPAN also motivates me to contribute to alleviating their suffering through basic research."

Contact us
Prof. Dr. rer. nat. Tassula Proikas-Cezanne
University of Tübingen
Department of Molecular Biology
Interfaculty Institute for Cell Biology (IFIZ)
Phone +49 7071 29-78895
tassula.proikas-cezanne@uni-tuebingen.de

 

Source: Press release of the University of Tübingen

8th NBIA Family Conference in Germany 2018

8th NBIA Family Conference in Germany 2018

From September 21 to 22, 2018, our 8th NBIA Family Conference took place in Düsseldorf with more than 75 participants. In addition to family members and those affected, the participants included doctors, scientists and a team of youth workers.

Most of the guests had already arrived the day before. After dinner together, we were able to enjoy the warm summer evening on the beautiful terrace of the youth hostel. Friends met up again and contacts were quickly made with the many new families. Even before the actual conference began, everyone felt that we were a community.

On Friday morning, the program began with a round of introductions of all those present. NBIA - Where do we stand in research and care? was our main topic. The varied medical lecture program was supported by simultaneous interpreters, as several speakers as well as some families from abroad were present. We would like to thank the many NBIA doctors and researchers who took the time to tell us families about their work.

The morning was initially dedicated to clinical care and research at NBIA:

Professor Dr. Thomas Klopstock, head of the NBIA team at the Friedrich Baur Institute of the Neurological University Hospital in Munich, provided groundbreaking insights into the current state of clinical research and symptomatic treatment options for PKAN and other NBIA variants. Dr. Ivan Karin (Friedrich Baur Institute, Munich) spoke about the similarities and differences between the various NBIA diseases. Dr. Boriana Büchner, also from the Friedrich Baur Institute, then reported on the development of the International NBIA Patient Registry.

Dr. Matias Wagner from the Institute of Neurogenomics at the Helmholtz Centre in Munich provided information on the possibilities of genetic diagnostics for NBIA. He drew attention to the genetic counseling to which all patients and their families in Germany are entitled. It quickly became clear that this topic is of concern to all NBIA patients.

After the lunch break, Markus Nielbock, father of a 6-year-old daughter with BPAN, reported on the everyday life of an NBIA family and thus contributed the experiences of those affected - on behalf of many of our families with a similar fate.

Dr. Kristina Müller, Chief Physician at the St. Mauritius Neuropaediatric Therapy Clinic in Meerbusch, gave a vivid presentation on the possibilities of rehabilitation for children and adolescents with a neurodegenerative disease.

The presentation by Dr. Tomasz Kmiec from the Children's Memorial Health Institute in Warsaw focused on the clinical symptoms and the unfortunately very limited therapeutic options for MPAN.

After this more clinically oriented group of topics, things became very scientific:

Professor Ody Sibon from the University of Groningen presented the path from basic research to clinical trials in PKAN. Her presentation focused on a current PKAN therapy project that she is working on in collaboration with Dr. Susan Hayflick from the University Hospital in Oregon.
Dr. Arcangela Iuso from the Institute of Human Genetics at the Technical University of Munich presented the International NBIA Biobank as well as preclinical NBIA projects for MPAN and BPAN, in which disease-specific animal models are used.
Not only the families, but also the doctors and scientists were excited about the presentation by Dr. Agnès Rötig, geneticist at the Imagine Institute of the University of Paris Descartes. She presented a common disease mechanism in a number of NBIA variants.
After each block of presentations, there were lively rounds of questions and discussions between all those present.

Parallel to the lecture program, some parents whose children had died of NBIA in recent years met for a discussion group for grieving families. This discussion group was sensitively led by Ursula Hofmann and Michaela Schürer, both long-standing board members of Hoffnungsbaum e.V.

For the children and young people who came to the conference, an entertaining leisure program took place throughout the sessions on both days of the conference, with games, crafts and a walk along the banks of the Rhine. Our very special thanks go to our wonderful team of supervisors from the Catholic parish in Velbert, who took on this task on a voluntary basis for the 8th time now. They were supported on Friday by the Düsseldorf puppeteer Frank, who came along with his folding mouth puppets.

On Friday evening, there was a delicious dinner with grilled food and salads, followed by a relaxed and cheerful get-together until late into the night.

On Saturday morning, we first commemorated the people who have lost their struggle with NBIA. After a break, the annual general meeting of Hoffnungsbaum e.V. took place. We will report on this separately soon.

On Saturday afternoon, there were also insights into the international NBIA patient community. Hoffnungsbaum Chairwoman Angelika Klucken presented the origins and projects of the NBIA Alliance, the international umbrella organization for currently 9 NBIA patient associations.
Fatemeh Mollet from Switzerland then reported on the NBIA patient organization she founded, NBIA Suisse. Ms. Mollet, who comes from Iran and has 3 nieces with MPAN there, is also the founder of an NBIA support group in Iran. Thanks to her great commitment, NBIA Suisse has already been able to award two grants to the Technical University of Munich for the multi-year research project "Therapeutic strategies for the treatment of MPAN patients".

The families present enjoyed the many personal encounters and we said goodbye to each other late on Saturday afternoon with lots of hugs. The unanimous feedback was: a great conference and we are already looking forward to the next one.

This successful conference would not have been possible without our sponsors, Techniker Krankenkasse, the Kindness for Kids Foundation and a fundraising campaign by the Gabasch family. We would like to thank them for their financial support.

Photo: Valerie Baumann

News from Milly and her mission

News from Milly and her mission

Milly

On 22.12.2017, Rhein-Neckar-Fernsehen (RNF) presented Milly and her family in the program RNFlife:

http://www.rnf.de/mediathek/video/heidelberg-wie-die-kleine-emilia-gegen-ihre-gen-krankheit-ankaempft/

Emilia has BPAN. About a year ago, the parents of 5-year-old Milly, Rebecca and Markus Nielbock, received the diagnosis. Soon afterwards, they contacted Hoffnungsbaum e.V. and the family joined our NBIA self-help organization. In the summer of 2017, the Nielbock family started their own Website under the name "Milly's Mission" launched a fundraising campaign to support BPAN research.

On the website you will also learn more about Milly and her family's touching story and get an insight into Milly's life with this subtype of NBIA, which was first described in 2012, the year Milly was born, and is currently one of the fastest growing NBIA patient groups.

In the meantime Hoffnungsbaum e.V. more than €4,500 has been raised for BPAN research. You can continue to help research treatment options for BPAN. On this Donation homepage to find out more. Important: Please always mark your donation for BPAN research with "BPAN"!

In addition, on 12.01.2018 the Rhine-Neckar Newspaper about Milly and the fundraising campaign for BPAN research.

In a few months' time, the donations collected by then will be used to fund a BPAN research grant, which will be awarded by the NBIA Disorders Association.

Photo: Sonia Epple

TIRCON project ended with final conference in October 2015

TIRCON project ended with final conference in October 2015

In October 2015, the international research project TIRCON ("Treat Iron-Related Childhood-Onset Neurodegeneration"), which was funded by the European Union for four years, ended as planned. This event was celebrated with a major final conference on October 15 and 16, 2015 in Munich with around 90 participants.

The project partners, including clinicians, basic researchers and representatives of pharmaceutical companies and the patient organizations NBIA Disorders Association and Hoffnungsbaum e.V.presented the project results and the developments in NBIA research achieved through TIRCON to the attendees. Guests included our partner organizations from the NBIA Alliance as well as physicians working at clinical centers from Germany, Iran, Italy, Canada, Serbia, Spain, the Czech Republic and Hungary. (Information on the presentations can also be found in the Conference program remove)

In addition, future-oriented workshops were held at the final conference, in which the TIRCON consortium discussed research strategies and new project plans together with other scientists. The workshops were initiated and co-organized by Hoffnungsbaum e.V. and co-organized.

Even after the conclusion of TIRCON, collaborations and working meetings will continue and projects that have already been started will be continued, for example the evaluation of the study results and the continuation of the NBIA infrastructure that has been set up, such as the patient register and biobank.

Subscribe to our Hoffnungsbaum newsletter!

With our newsletter e-mails you will receive valuable information about NBIA. If you would like to receive additional information on individual NBIA variants or special information for researchers/clinicians in addition to the general newsletter, please click here: Subscribe to additional information

Privacy policy

You have successfully registered!